Dual-targeted nanomedicines for enhanced tumor treatment. (February 2018)

• Record Type: Journal Article
• Authors: Zhu, Yaqin; Feijen, Jan; Zhong, Zhiyuan
• Is Part Of: Nano today. Volume 18(2018)
• Page Start: 65
• Page End: 85
• Publication Date: 2018-02
• Subjects: ADCs antibody drug conjugates -- ApoE apolipoprotein E -- BBB blood-brain barrier -- BCECs brain capillary endothelial cells -- BCSCs breast cancer stem cells -- BSA bovine serum albumin -- CD44 cluster determinant 44 -- CPPs cell-penetrating peptides -- CYC cyclopamine -- DBCO dibenzocyclooctyl -- DOX doxorubicin -- DSPE distearoyl phosphoethanolamine -- DTX docetaxel -- ECM extracellular matrix -- EGF epidermal growth factor -- EGFR epidermal growth factor receptor -- EMA European Medicines Agencies -- EPR enhanced permeability and retention -- ER estrogen receptor -- FA folic acid -- FDA US Food and Drug Administration -- FR folic acid receptor -- GTC galactose-modified trimethyl chitosan-cysteine -- HA hyaluronic acid -- HSPGs heparin sulfate proteoglycans -- HER2 human epidermal growth factor receptor-2 -- HUVEC human umbilical vein endothelial cell -- IFP interstitial fluid pressure -- L-Cys l-cysteine -- LDL low density lipoprotein -- Lf lactoferrin -- LfR lactoferrin receptor -- LRP low-density lipoprotein receptor-related protein -- MAL maleimide -- MDR multidrug resistance -- MMP-2 matrix metalloprotease 2 -- MRI magnetic resonance imaging -- MSNs mesoporous silica nanoparticles -- NGR Asn-Gly-Arg -- Sulfo-NHS N-hydroxysulfosuccinimide -- NRP1 neuropilin-1 -- PAMAM poly (amidoamine) -- PCL poly(ε-caprolactone) -- PE phosphatidylethanolamine -- PEG polyethylene glycol -- PEI polyethyleneimine -- P-gp P-glycoprotein -- PLGA poly (lactic-co-glycolic acid) -- PPE polyphosphoester -- PTX paclitaxel -- QD quantum dots -- RES reticuloendothelial system -- RGD Arg-Gly-Asp -- SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis -- SLNs solid lipid nanoparticles -- SP substance P -- STR-RX stearylated oligoarginine -- tetrac tetraiodothyroacetic acid -- Tf transferrin -- TfR transferrin receptor -- TGN TGNYKALHPHNG -- TPP triphenylphosphonium -- VEGF vascular endothelial growth factor -- VEGFR vascular endothelial growth factor receptor; Nanomedicine -- Dual-ligand -- Tumor-targeted delivery -- Tumor therapy -- Receptor-mediated endocytosis -- Cell-penetrating peptides -- Targeting efficacy; Nanotechnology -- Periodicals; Nanosciences -- Périodiques; 620.505
• DOI: 10.1016/j.nantod.2017.12.007
• Languages: English
• ISSNs: 1748-0132

Abstract

Graphical abstract: Highlights: Different types of dual-ligand nanomedicines for tumor-targeted imaging and therapy. Advantages of dual-ligand nanomedicines in tumor-targeting. Factors that affect the targeting efficacy of dual-ligand nanomedicines. The role of cell penetrating peptides in combination with targeting ligands. Approaches for improved design and evaluation of the effect of dual-ligand nanomedicines. Abstract: Based on the overexpression of specific receptors on tumor cells, active targeting nanomedicines have been developed with the ability to efficiently deliver imaging agents in the tumor area or anticancer drugs into tumor cells via receptor-mediated endocytosis. Nevertheless, the efficacy of single-ligand nanomedicines is still limited due to the complexity of the tumor microenvironment. In recent years, dual-ligand nanomedicines have attracted a lot of interest, because these nanomedicines endowed with versatile functions, have the potential to improve the efficacy of tumor-targeted delivery. In this review, an overview of various dual-ligand nanomedicines for tumor targeted therapy will be presented, the role of cell penetrating peptides in combination with targeting ligands will be discussed and factors that affect the targeting efficacy of dual-ligand nanomedicines will be evaluated.